<DOC>
	<DOCNO>NCT02006693</DOCNO>
	<brief_summary>The objective study evaluate AqueSys XEN Implant treatment moderate primary open angle glaucoma patient medication fail control intraocular pressure ( IOP ) . Effectiveness evaluate compare medicate preoperative , intraocular pressure postoperative value . Additionally , number IOP lower medication subject study visit compare preoperative medication .</brief_summary>
	<brief_title>Evaluation XEN Implant Moderate POAG Subjects</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<criteria>Diagnosis primary open angle glaucoma Subjects take least one four IOP lower medication . Angle Closure Glaucoma Subject neovascular , uveitic angle recession glaucoma glaucoma associate vascular disorder Clinically significant inflammation infection study eye within 30 day prior preoperative visit ( e.g. , blepharitis , conjunctivitis , keratitis , uveitis , herpes simplex infection ) Presence conjunctival scar prior conjunctival surgery conjunctival pathology ( e.g. , pterygium ) target quadrant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>XEN</keyword>
	<keyword>Primary Open Angle Glaucoma</keyword>
	<keyword>Filtration Device</keyword>
	<keyword>Ab interno</keyword>
</DOC>